Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis

Pharmacology and Therapeutics

Volumn 131, Issue 1, 2011, Pages 80-90

  Larsen, Annette K ^a,b,c   Ouaret, Djamila ^a,b,c   El Ouadrani, Karima ^a,b,c   Petitprez, Amélie ^a,b,c,d  

^a HÔPITAL SAINT ANTOINE   (France)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Drug combinations; EGFR; Molecular targeted anticancer agents; Monoclonal antibodies; Signaling cross talk; Tumor angiogenesis; Tumor cell survival; Tyrosine kinase inhibitors; VEGF(R)

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AFATINIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AXITINIB; AZ 2171; B RAF KINASE; BAY 549085; BEVACIZUMAB; CANERTINIB; CEDIRANIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTEDANIB; K RAS PROTEIN; LAPATINIB; NEUROPILIN 1; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 3;

ACUTE HEMORRHAGIC PANCREATITIS; ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; DIARRHEA; DOWN REGULATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; ENDOTHELIUM CELL; ENZYME INHIBITION; EPIDERMOID TUMOR; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK CARCINOMA; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TRANSLATION REGULATION; TUMOR PROMOTION; TUMOR VASCULARIZATION;

EID: 79956205502     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2011.03.012     Document Type: Review

References (106)

1. K. Al-Nedawi, B. Meehan, R.S. Kerbel, A.C. Allison, and J. Rak Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR Proc Natl Acad Sci USA 106 2009 3794 3799
2. D.N. Amin, K. Hida, D.R. Bielenberg, and M. Klagsbrun Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors Cancer Res 66 2006 2173 2180
3. D.N. Amin, D.R. Bielenberg, E. Lifshits, J.V. Heymach, and M. Klagsbrun Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells Microvasc Res 76 2008 15 22
4. R. Avraham, and Y. Yarden Feedback regulation of EGFR signalling: decision making by early and delayed loops Nat Rev Mol Cell Biol 12 2011 104 117
5. A. Azzariti, J.M. Xu, L. Porcelli, and A. Paradiso The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839) Biochem Pharmacol 68 2004 135 144 (Pubitemid 38746549)
6. R.E. Bachelder, A. Crago, J. Chung, M.A. Wendt, L.M. Shaw, and G. Robinson Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells Cancer Res 61 2001 5736 5740 (Pubitemid 32769088)
7. C.H. Baker, D. Kedar, M.F. McCarty, R. Tsan, K.L. Weber, and C.D. Bucana Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas Am J Pathol 161 2002 929 938 (Pubitemid 34988380)
8. R.C. Bates, J.D. Goldsmith, R.E. Bachelder, C. Brown, M. Shibuya, and P. Oettgen Flt-1-dependent survival characterizes the epithelial-mesenchymal transition of colonic organoids Curr Biol 13 2003 1721 17277
9. R. Bianco, R. Rosa, V. Damiano, G. Daniele, T. Gelardi, and S. Garofalo Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells Clin Cancer Res 14 2008 5069 5080
10. O. Bouché, M. Ducreux, G. Lledo, T. André, F. Maindrault-Goebel, and P. Stopfer A phase II trial of weekly alternating sequential administration of BIBF 1120 and BIBW 2992 in patients with advanced colorectal cancer J Clin Oncol 26 2008 (May 20 suppl; abstr 15001)
11. C.P. Bracken, A.O. Fedele, S. Linke, W. Balrak, K. Lisy, and M.L. Whitelaw Cell-specific regulation of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha stabilization and transactivation in a graded oxygen environment J Biol Chem 281 2006 22575 22585
12. C.J. Bruns, C.C. Solorzano, M.T. Harbison, S. Ozawa, R. Tsan, and D. Fan Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma Cancer Res 60 2000 2926 2935 (Pubitemid 30395817)
13. E. Buck, A. Eyzaguirre, J.D. Haley, N.W. Gibson, P. Cagnoni, and K.K. Iwata Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity Mol Cancer Ther 5 2006 2051 2059 (Pubitemid 44336577)
14. O. Casanovas, D.J. Hicklin, G. Bergers, and D. Hanahan Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell 8 2005 299 309 (Pubitemid 41443415)
15. Y. Chen, L. Jiang, F. She, N. Tang, X. Wang, and X. Li Vascular endothelial growth factor-C promotes the growth and invasion of gallbladder cancer via an autocrine mechanism Mol Cell Biochem 345 2010 77 89
16. K.Y. Chung, J. Shia, N.E. Kemeny, M. Shah, G.K. Schwartz, and A. Tse Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry J Clin Oncol 23 2005 1803 1810 (Pubitemid 46211358)
17. A.S. Chung, J. Lee, and N. Ferrara Targeting the tumour vasculature: insights from physiological angiogenesis Nat Rev Cancer 10 2010 505 514
18. F. Ciardiello, R. Bianco, V. Damiano, G. Fontanini, R. Caputo, and G. Pomatico Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells Clin Cancer Res 6 2000 3739 3747
19. F. Ciardiello, R. Caputo, R. Bianco, V. Damiano, G. Fontanini, and S. Cuccato Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor Clin Cancer Res 7 2001 1459 1465 (Pubitemid 32708703)
20. A. Citri, I. Alroy, S. Lavi, C. Rubin, W. Xu, and N. Grammatikakis Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy EMBO J 21 2002 2407 2417 (Pubitemid 34546713)
21. M. Detmar, L.F. Brown, K.P. Claffey, K.T. Yeo, O. Kocher, and R.W. Jackman Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis J Exp Med 180 1994 1141 1146 (Pubitemid 24256627)
22. S. Dias, M. Choy, K. Alitalo, and S. Rafii Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy Blood 99 2002 2179 2184 (Pubitemid 34525504)
23. D. Dutta, S. Ray, J.L. Vivian, and S. Paul Activation of the VEGFR1 chromatin domain: an angiogenic signal-ETS1/HIF-2alpha regulatory axis J Biol Chem 283 2008 25404 25413
24. J.M. Ebos, C.R. Lee, W. Cruz-Munoz, G.A. Bjarnason, J.G. Christensen, and R.S. Kerbel Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Cancer Cell 15 2009 232 239
25. F. Fan, J.S. Wey, M.F. McCarty, A. Belcheva, W. Liu, and T.W. Bauer Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells Oncogene 24 2005 2647 2653 (Pubitemid 40593092)
26. F. Fan, M.J. Gray, N.A. Dallas, A.D. Yang, G. Van Buren 2nd, and E.R. Camp Effect of chemotherapeutic stress on induction of vascular endothelial growth factor family members and receptors in human colorectal cancer cells Mol Cancer Ther 7 2008 3064 3070
27. J. Folkman Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6 2007 273 286 (Pubitemid 46505878)
28. A. Franovic, L. Gunaratnam, K. Smith, I. Robert, D. Patten, and S. Lee Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer Proc Natl Acad Sci USA 104 2007 13092 13097 (Pubitemid 351737598)
29. A. Franovic, C.E. Holterman, J. Payette, and S. Lee Human cancers converge at the HIF-2alpha oncogenic axis Proc Natl Acad Sci USA 106 2009 21306 21311
30. D. Fukumura, and R.K. Jain Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize J Cell Biochem 101 2007 937 949 (Pubitemid 47040874)
31. R. Garcia, T.L. Bowman, G. Niu, H. Yu, S. Minton, and C.A. Muro-Cacho Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells Oncogene 20 2001 2499 2513 (Pubitemid 32531347)
32. S. Ghosh, C.A. Sullivan, M.P. Zerkowski, A.M. Molinaro, D.L. Rimm, and R.L. Camp High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer Hum Pathol 39 2008 1835 1843
33. C.K. Goldman, J. Kim, W.L. Wong, V. King, T. Brock, and G.Y. Gillespie Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology Mol Biol Cell 4 1993 121 133 (Pubitemid 23071308)
34. L. Gossage, and T. Eisen Targeting multiple kinase pathways: a change in paradigm Clin Cancer Res 16 2010 1973 1978
35. M.J. Gray, G. Van Buren, N.A. Dallas, L. Xia, X. Wang, and A.D. Yang Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver J Natl Cancer Inst 100 2008 109 120 (Pubitemid 351480563)
36. J.D. Hainsworth, J.A. Sosman, D.R. Spigel, D.L. Edwards, C. Baughman, and A. Greco Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib J Clin Oncol 23 2005 7889 7896 (Pubitemid 46657387)
37. J.R. Hecht, E. Mitchell, T. Chidiac, C. Scroggin, C. Hagenstad, and D. Spigel A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer J Clin Oncol 27 2009 672 680
38. R.S. Herbst, D.H. Johnson, E. Mininberg, D.P. Carbone, T. Henderson, and E.S. Kim Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer J Clin Oncol 23 2005 2544 2555
39. K. Hida, Y. Hida, D.N. Amin, A.F. Flint, D. Panigrahy, and C.C. Morton Tumor-associated endothelial cells with cytogenetic abnormalities Cancer Res 64 2004 8249 8255 (Pubitemid 39491762)
40. F. Hilberg, G.J. Roth, M. Krssak, S. Kautschitsch, W. Sommergruber, and U. Tontsch-Grunt BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy Cancer Res 68 2008 4774 4782
41. C.J. Hu, A. Sataur, L. Wang, H. Chen, and M.C. Simon The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha Mol Biol Cell 18 2007 4528 4542 (Pubitemid 350060179)
42. D.D. Hu-Lowe, H.Y. Zou, M.L. Grazzini, M.E. Hallin, G.R. Wickman, and K. Amundson Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3 Clin Cancer Res 14 2008 7272 7283
43. N.E. Hynes, and G. MacDonald ErbB receptors and signaling pathways in cancer Curr Opin Cell Biol 21 2009 177 184
44. R.K. Jain, R.T. Tong, and L.L. Munn Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model Cancer Res 67 2007 2729 2735 (Pubitemid 46548961)
45. H. Kikuchi, M.S. Pino, M. Zeng, S. Shirasawa, and D.C. Chung Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer Cancer Res 69 2009 8499 8506
46. H.S. Kim, H.S. Shin, H.J. Kwak, C.H. Cho, C.O. Lee, and G.Y. Koh Betacellulin induces angiogenesis through activation of mitogen-activated protein kinase and phosphatidylinositol 3'-kinase in endothelial cell FASEB J 17 2003 318 320
47. M. Kodama, Y. Kitadai, M. Tanaka, T. Kuwai, S. Tanaka, and N. Oue Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms Clin Cancer Res 14 2008 7205 7214
48. T. Kuwai, T. Nakamura, T. Sasaki, S.J. Kim, D. Fan, and G.J. Villares Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors Neoplasia 10 2008 489 500 (Pubitemid 351657391)
49. A.K. Larsen, V. Poindessous, D. Ouaret, K. El Ouadrani, and V.F. Megalophonos Combining EGFR- and VEGF(R)-targeted agents in colorectal cancer should be possible J Clin Oncol 29 2011 (suppl 4; abstr 443)
50. S. Lee, T.T. Chen, C.L. Barber, M.C. Jordan, J. Murdock, and S. Desai Autocrine VEGF signaling is required for vascular homeostasis Cell 130 2007 691 703 (Pubitemid 47268059)
51. T.H. Lee, S. Seng, M. Sekine, C. Hinton, Y. Fu, and H.K. Avraham Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1 PLoS Med 4 2007 e186
52. Y.J. Lee, D.L. Karl, U.N. Maduekwe, C. Rothrock, S. Ryeom, and P.A. D'Amore Differential effects of VEGFR-1 and VEGFR-2 inhibition on tumor metastases based on host organ environment Cancer Res 70 2010 8357 8367
53. M.A. Lemmon, and J. Schlessinger Cell signaling by receptor tyrosine kinases Cell 141 2010 1117 1134
54. X. Li, and Z. Fan The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex Cancer Res 70 2010 5942 5952
55. D. Li, L. Ambrogio, T. Shimamura, S. Kubo, M. Takahashi, and L.R. Chirieac BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Oncogene 27 2008 4702 4711
56. X. Li, Y. Lu, K. Liang, T. Pan, J. Mendelsohn, and Z. Fan Requirement of hypoxia-inducible factor-1alpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab Mol Cancer Ther 7 2008 1207 1217
57. B.M. Lichtenberger, P.K. Tan, H. Niederleithner, N. Ferrara, P. Petzelbauer, and M. Sibilia Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development Cell 140 2010 268 279
58. H.W. Lo, S.C. Hsu, M. Ali-Seyed, M. Gunduz, W. Xia, and Y. Wei Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway Cancer Cell 7 2005 575 589 (Pubitemid 40799250)
59. R.B. Luwor, Y. Lu, X. Li, J. Mendelsohn, and Z. Fan The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression Oncogene 24 2005 4433 4441 (Pubitemid 40961766)
60. P.H. Maxwell, M.S. Wiesener, G.W. Chang, S.C. Clifford, E.C. Vaux, and M.E. Cockman The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis Nature 399 1999 271 275 (Pubitemid 29246458)
61. S. Mittar, C. Ulyatt, G.J. Howell, A.F. Bruns, I. Zachary, and J.H. Walker VEGFR1 receptor tyrosine kinase localization to the Golgi apparatus is calcium-dependent Exp Cell Res 315 2009 877 889
62. M.P. Morelli, A.M. Brown, T.M. Pitts, J.J. Tentler, F. Ciardiello, and A. Ryan Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines Mol Cancer Ther 8 2009 2546 2558
63. S. Naik, R.S. Dothager, J. Marasa, C.L. Lewis, and D. Piwnica-Worms Vascular endothelial growth factor receptor-1 is synthetic lethal to aberrant {beta}-catenin activation in colon cancer Clin Cancer Res 15 2009 7529 7537
64. G.N. Naumov, M.B. Nilsson, T. Cascone, A. Briggs, O. Straume, and L.A. Akslen Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance Clin Cancer Res 15 2009 3484 3494
65. G. Niu, K.L. Wright, M. Huang, L. Song, E. Haura, and J. Turkson Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis Oncogene 21 2002 2000 2008 (Pubitemid 34270888)
66. M. Pàez-Ribes, E. Allen, J. Hudock, T. Takeda, H. Okuyama, and F. Viñals Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 15 2009 220 231
67. A.A. Parikh, F. Fan, W.B. Liu, S.A. Ahmad, O. Stoeltzing, and N. Reinmuth Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis Am J Pathol 164 2004 2139 2151 (Pubitemid 38669361)
68. O.K. Park, T.S. Schaefer, and D. Nathans In vitro activation of Stat3 by epidermal growth factor receptor kinase Proc Natl Acad Sci USA 93 1996 13704 13708 (Pubitemid 26424183)
69. A.M. Petit, J. Rak, M.C. Hung, P. Rockwell, N. Goldstein, B. Fendly, and R.S. Kerbel Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors Am J Pathol 151 1997 1523 1530 (Pubitemid 27527914)
70. N. Pore, Z. Jiang, A. Gupta, G. Cerniglia, G.D. Kao, and A. Maity EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms Cancer Res 66 2006 3197 3204
71. C.J.A. Punt, and J. Tol More is less-combining targeted therapies in metastatic colorectal cancer Nat Rev Clin Oncol 6 2009 731 733
72. A. Rapisarda, B. Uranchimeg, D.A. Scudiero, M. Selby, E.A. Sausville, and R.H. Shoemaker Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway Cancer Res 62 2002 4316 4324 (Pubitemid 34827288)
73. F. Riedel, K. Götte, M. Li, K. Hörmann, and J.R. Grandis EGFR antisense treatment of human HNSCC cell lines down-regulates VEGF expression and endothelial cell migration Int J Oncol 21 2002 11 16
74. P.J. Roberts, T.E. Stinchcombe, C.J. Der, and M.A. Socinski Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 28 2010 4769 4777
75. K. Roepstorff, M.V. Grandal, L. Henriksen, S.L.J. Knudsen, M. Lerdrup, and L. Grøvdal Differential effects of EGFR ligands on endocytic sorting of the receptor Traffic 10 2009 1115 1127
76. G.M. Ruinemans, C. Balemans, V. Mattijssen, A.J. Wiersma-van Tilburg, and H.J. Smit Fatal necrotizing pancreatitis during combined treatment with erlotinib and sunitinib Lung Cancer 70 2010 364 365
77. P. Saintigny, M. Kambouchner, M. Ly, N. Gomes, O. Sainte-Catherine, and R. Vassy Vascular endothelial growth factor-C and its receptor VEGFR-3 in non-small-cell lung cancer: concurrent expression in cancer cells from primary tumour and metastatic lymph node Lung Cancer 58 2007 205 213 (Pubitemid 47513253)
78. L.B. Saltz, H.J. Lenz, H.L. Kindler, H.S. Hochster, S. Wadler, and P.M. Hoff Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study J Clin Oncol 25 2007 4557 4561 (Pubitemid 350035312)
79. S. Samuel, F. Fan, L.H. Dang, L. Xia, P. Gaur, and L.M. Ellis Intracrine vascular endothelial growth factor signaling in survival and chemoresistance of human colorectal cancer cells Oncogene 30 2011 1205 1212
80. G.L. Semenza Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics Oncogene 29 2010 625 634
81. R.M. Shaheen, S.A. Ahmad, W. Liu, N. Reinmuth, Y.D. Jung, and W.W. Tseng Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors Br J Cancer 85 2001 584 589 (Pubitemid 32808285)
82. S. Siena, A. Sartore-Bianchi, F. Di Nicolantonio, J. Balfour, and A. Bardelli Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer J Natl Cancer Inst 101 2009 1308 1324
83. P. Sini, L. Wyder, C. Schnell, T. O'Reilly, A. Littlewood, and R. Brandt The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade Clin Cancer Res 11 2005 4521 4532 (Pubitemid 40825643)
84. S. Soker, S. Takashima, H.Q. Miao, G. Neufeld, and M. Klagsbrun Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor Cell 92 1998 735 745 (Pubitemid 28155313)
85. A. Sorkin, and L.K. Goh Endocytosis and intracellular trafficking of ErbBs Exp Cell Res 315 2009 683 696
86. A. Sorkin, and M. von Zastrow Endocytosis and signalling: intertwining molecular networks Nat Rev Mol Cell Biol 10 2009 609 622
87. J.B. Spangler, J.R. Neil, S. Abramovitch, Y. Yarden, F.M. White, and D.A. Lauffenburger Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling Proc Natl Acad Sci USA 107 2010 13252 13257
88. H. Sunada, B.E. Magun, J. Mendelsohn, and C.L. MacLeod Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation Proc Natl Acad Sci USA 83 1986 3825 3829 (Pubitemid 16062376)
89. D.E. Swinson, J.L. Jones, G. Cox, D. Richardson, A.L. Harris, and K.J. O'Byrne Hypoxia-inducible factor-1 alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathways Int J Cancer 111 2004 43 50 (Pubitemid 38859281)
90. K.L. Talks, H. Turley, K.C. Gatter, P.H. Maxwell, C.W. Pugh, and P.J. Ratcliffe The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages Am J Pathol 157 2000 411 421 (Pubitemid 30626905)
91. J. Tol, M. Koopman, A. Cats, C.J. Rodenburg, G.J. Creemers, and J.G. Schrama Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer N Engl J Med 360 2009 563 572
92. J.R. Tonra, D.S. Deevi, E. Corcoran, H. Li, S. Wang, and F.E. Carrick Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy Clin Cancer Res 12 2006 2197 2207
93. P. Traxler, P.R. Allegrini, R. Brandt, J. Brueggen, R. Cozens, and D. Fabbro AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity Cancer Res 64 2004 4931 4941 (Pubitemid 38924540)
94. A. Viloria-Petit, T. Crombet, S. Jothy, D. Hicklin, P. Bohlen, and J.M. Schlaeppi Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis Cancer Res 61 2001 5090 5101 (Pubitemid 32681540)
95. L.S. Wanami, H.Y. Chen, S. Peiró, A. García de Herreros, and R.E. Bachelder Vascular endothelial growth factor-A stimulates Snail expression in breast tumor cells: implications for tumor progression Exp Cell Res 314 2008 2448 2453
96. Y. Wang, O. Roche, M.S. Yan, G. Finak, A.J. Evans, and J.L. Metcalf Regulation of endocytosis via the oxygen-sensing pathway Nat Med 15 2009 319 324
97. Y.N. Wang, H. Yamaguchi, J.M. Hsu, and M.C. Hung Nuclear trafficking of the epidermal growth factor receptor family membrane proteins Oncogene 29 2010 3997 4006
98. S.E. Wang, Y. Yu, T.L. Criswell, L.M. Debusk, P.C. Lin, and R. Zent Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators Oncogene 29 2010 3335 3348
99. S.R. Wedge, D.J. Ogilvie, M. Dukes, J. Kendrew, R. Chester, and J.A. Jackson ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration Cancer Res 62 2002 4645 4655
100. Z. Weihua, R. Tsan, W.C. Huang, Q. Wu, C.H. Chiu, and I.J. Fidler Survival of cancer cells is maintained by EGFR independent of its kinase activity Cancer Cell 13 2008 385 393 (Pubitemid 351609444)
101. G.B. Whitaker, B.J. Limberg, and J.S. Rosenbaum Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF(165) and VEGF(121) J Biol Chem 276 2001 25520 25531
102. F. Winkler, S.V. Kozin, R.T. Tong, S.S. Chae, M.F. Booth, and I. Garkavtsev Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases Cancer Cell 6 2004 553 563 (Pubitemid 40017699)
103. L. Yen, X.L. You, A.E. Al Moustafa, G. Batist, N.E. Hynes, and S. Mader Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis Oncogene 19 2000 3460 3469 (Pubitemid 30487443)
104. K. Yokoi, P.H. Thaker, S. Yazici, R.R. Rebhun, D.H. Nam, and J. He Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model Cancer Res 65 2005 3716 3725 (Pubitemid 40616349)
105. Z. Zhang, K.G. Neiva, M.W. Lingen, L.M. Ellis, and J.E. Nör VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2 Cell Death Differ 17 2010 499 512
106. S. Zhang, H.E. Zhau, A.O. Osunkoya, S. Iqbal, X. Yang, and S. Fan Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells Mol Cancer 9 2010 9 10.1186/1476-4598-9-9